10 results about "Etoricoxib" patented technology

The invention provides an etoricoxib injection concentrated solution which is large in unit dose, can remarkably improve the production efficiency of unit dose products, and can be used after being compatible with a clinically available diluent. Meanwhile, the injection concentrated solution and the solution obtained after compatibility of the diluent are high in stability, and the clinical administration requirement is met.

This invention is entitled "A Method for Preparing an Intermediate of Aericoxib," belonging to the field of pharmaceutical preparation technology. The technical problem to be solved is to provide a method for preparing an intermediate of Aericoxib that is simple to operate, uses readily available raw materials, and has simple post-processing. The key points of the technical solution are that the preparation method includes the following steps: (1) 2-bromo-1-(4-methanesulfonyl)acetophenone, hexamethylenetetramine and solvent are reacted, filtered, hydrochloric acid and methanol are added, and the reaction is continued to obtain 2-amino-1-(4-methanesulfonyl)acetophenone hydrochloride; (2) 2-amino-1-(4-methanesulfonyl)acetophenone hydrochloride, p-methylphenylacetic acid, base 1 and solvent are mixed, reacted, cooled to -5℃-15℃, base 2 and 1-bromopropane are added, and the reaction is continued to obtain the intermediate.

This invention provides a method for preparing etoricoxib intermediate A. The method includes: by using a specified solvent and a basic reagent in combination, the yield and purity of intermediate A are significantly improved, the production cost is reduced, and it is suitable for industrial production.

The invention discloses etomidate immunofluorescence chromatography rapid detection test paper and a detection method, and relates to the technical field of qualitative identification and drug detection. The etomidate immunofluorescence chromatography rapid detection test paper comprises a bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad, the nitrocellulose membrane is attached to the bottom plate, the water absorption pad and the combination pad are tightly connected with the two ends of the nitrocellulose membrane in a pressing mode respectively, and the sample pad is tightly connected with the end, away from the nitrocellulose membrane, of the combination pad in a pressing mode; a detection line and a quality control line are sequentially arranged on the nitrocellulose membrane from one end close to the conjugate pad to one end far away from the conjugate pad. The immunofluorescence chromatography test paper can be applied to rapid detection of etomidate, and has strong detection specificity and high sensitivity. The method provided by the invention provides powerful technical support for on-site rapid detection work and high-throughput screening of etomidate.

The invention provides an etomidate derivative as well as a preparation method and application thereof, and belongs to the field of chemical medicines. Compared with etomidate, the etomidate derivative disclosed by the invention has the advantage that the anesthesia time is remarkably shortened. The anesthesia time is shortened, so that some side effects after anesthesia can be relieved; rapid recovery of the autonomous regulation ability of important organs of a patient and postoperative nursing are facilitated; and the risk of wake-up delay is reduced. The etomidate derivative provided by the invention has a good application prospect in preparation of anesthetic drugs for shortening anesthesia time.

This invention discloses a method for purifying etoricoxib impurities, comprising the following steps: Step (1) preparing a tetrahydrofuran reaction solution of etoricoxib; Step (2) washing the tetrahydrofuran reaction solution of etoricoxib with an inorganic alkali solution containing 1wt%-10wt% for 1-3 times, and after the last alkali wash, adding an appropriate amount of water and cooling to crystallize, finally obtaining the purified etoricoxib product. The method of this invention is simple and ingenious. It utilizes the difference that compound B (2-chloro-1,3-bis(dimethylamino)trimethylene hexafluorophosphate) has good solubility in alkaline water, while etoricoxib is almost insoluble in alkaline water, and develops a method to remove impurity compound B from etoricoxib by washing with alkaline water. The operation process for removing impurity compound B is simple, short in cycle and low in cost, which greatly reduces the preparation cost of qualified etoricoxib preparation raw materials, and ultimately allows patients to obtain low-cost and safe drugs.

1. The name of the design product: packing box (etoricoxib tablet). 2. The use of the design product: for packing product. 3. The design points of the design product: the combination of pattern and color. 4. The picture or photo that can best show the design points: design 1 front view. 5. The design contains color. 6. Design 1 is designated as the basic design.

This invention relates to the field of pharmaceutical technology, specifically disclosing an etodoxa acid small molecule hydrogel and its preparation method. The hydrogel is prepared by mixing etodoxa acid with three small molecule ligands (glucamine, arginine, and lysine). The morphological characteristics, thermodynamic properties, intermolecular interactions, and dissolution effects of the hydrogel were verified using SEM, rheological testing, DSC, XRPD, FTIR, and dissolution experiments. The preparation method is simple, involving mixing etodoxa acid with the small molecule ligands, adding a small amount of deionized water, and shaking. The resulting hydrogel significantly improves the solubility and dissolution / release rate of etodoxa acid. Compared to etodoxa acid crystals, the hydrogel exhibits significantly better solubility, dissolution / release rate in water than individual crystalline drugs or their physical mixtures, demonstrating the potential to improve the bioavailability of etodoxa acid. This provides a new formulation strategy for addressing the solubility defects of poorly soluble drugs and for combination drug use.

Provided in the present invention is a lyophilized Etoricoxib powder for injection. The lyophilized powder comprises: (A) 10-70% of Etoricoxib; (B) 0.1-10% of a wetting agent; and (C) 30-90% of a lyoprotectant, wherein the wetting agent is selected from at least one of oleic acid, oleate, cholic acid, or cholate. Further provided in the present invention are a method for preparing the lyophilized powder, a suspension containing the lyophilized powder, and use thereof. The lyophilized Etoricoxib powder for injection of the present invention has an appropriate particle size, maintains a stable particle size after reconstitution, and features good long-term storage stability. The prepared suspension can be quickly released to reach an effective therapeutic level after intravenous injection, has a long duration of action, and exhibits a better effect compared with parecoxib sodium, an analgesic injection commonly used in current clinical practice.

The invention relates to the technical field of chemical synthesis, in particular to a synthetic method of etoricoxib, which comprises the following steps: carrying out butt joint and oxidation on a compound 1 and a compound 2 in a reaction flask by a one-pot method to obtain 6-methyl-2-chloro-4-iodine-2, 3 '-dipyridyl, adding the obtained 6-methyl-2-chloro-4-iodine-2, 3'-dipyridyl into the reaction flask, and reacting to obtain the etoricoxib. Carrying out a substitution reaction on the etoricoxib and 3, 3 '-bipyridine to obtain 5-chloro-2-(6-methylpyridine-3-yl)-3-(4-methylsulfonyl phenyl) pyridine, namely etoricoxib; compared with the prior art, the method has two reaction steps, so that the kettle efficiency is greatly improved; the yield of the two steps is 80.1% and is increased by 24% compared with the yield of the original process, the cost of the used raw materials and reactants is low, and byproducts also have economic benefits.